Cargando…
Prevention of β Thalassemia in Northern Israel - a Cost-Benefit Analysis
BACKGROUND: β Thalassemia major is characterized by hemolytic anemia, ineffective erythropoiesis and hemosiderosis. About 4% of the world population carries a Thalassemia gene. Management includes blood transfusions and iron chelation. However, this treatment is costly, and population screening may...
Autores principales: | Koren, Ariel, Profeta, Lora, Zalman, Luci, Palmor, Haya, Levin, Carina, Zamir, Ronit Bril, Shalev, Stavit, Blondheim, Orna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965716/ https://www.ncbi.nlm.nih.gov/pubmed/24678389 http://dx.doi.org/10.4084/MJHID.2014.012 |
Ejemplares similares
-
Detection of β-Thalassemia Carriers by Red Cell Parameters Obtained from Automatic Counters using Mathematical Formulas
por: Roth, Idit Lachover, et al.
Publicado: (2018) -
Genetics of hearing loss in the Arab population of Northern Israel
por: Danial-Farran, Nada, et al.
Publicado: (2018) -
Comment to the Article “Prevention of B Thalassemia in Northern Israel - A Cost-Benefit Analysis” by Koren et al.1
por: Amato, Antonio
Publicado: (2014) -
Extracellular Vesicle MicroRNA That Are Involved in β-Thalassemia Complications
por: Levin, Carina, et al.
Publicado: (2021) -
Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis
por: Levin, Carina, et al.
Publicado: (2018)